News

Eli Lilly Will Be the Next $1 Trillion Stock
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Houston Public Media2d
Eli Lilly sues Houston-based compounding pharmacy over alleged ‘knockoff’ obesity, diabetes drugs
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
Analysts Maintain Buy Ratings on Eli Lilly Stock (LLY) as Q1 Earnings Loom
Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...
The Hill2d
Eli Lilly sues telehealth companies selling compounded Zepbound, Mounjaro
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...
Obesity drug boom has a new pecking order
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
North Penn Now4d
Alternatives to Compounded Semaglutide & Tirzepatide: Affordable & Effective Options for Patients In The USA
"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...